• In June 2026, Cleveland Clinic announced a multi-year research collaboration with 10x Genomics to use its Flex Apex, Xenium and future Atera platforms to analyze advanced bladder cancer tumor samples and uncover treatment-response biomarkers for potential diagnostic development.
• This partnership aims to generate a rich, multimodal dataset that links single-cell and spatial profiles with clinical outcomes, potentially reinforcing 10x Genomics’ role in precision oncology research and future diagnostic applications beyond bladder cancer.
• Next, we’ll examine how this Cleveland Clinic collaboration and its biomarker ambitions may influence 10x Genomics’ existing investment narrative.

Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe that single cell and spatial biology tools can become essential for translational and future diagnostic workflows, and that 10x’s platforms will remain among the preferred options. The Cleveland Clinic collaboration strengthens that thesis on the translational side, but it does not change near term priorities, which still hinge on stabilizing revenue growth while controlling losses, or the key risk that weaker research budgets and pricing pressure could weigh on both growth and margins.

Among recent announcements, the launch of the Atera in situ spatial biology platform in April 2026 looks most relevant here. The Cleveland Clinic study is expected to expand onto Atera, tying a flagship translational cancer project directly to one of 10x’s newest technologies. For investors, that connection links a major product launch to a visible use case in oncology, which could matter for how quickly Atera contributes to the company’s broader growth and ecosystem story.

Yet investors should also be aware that stretched academic funding could still...

10x Genomics’ narrative projects $709.8 million revenue and $110.2 million earnings by 2029.

Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 45% downside to its current price.

Exploring Other Perspectives

While this Cleveland Clinic deal highlights potential new diagnostic use cases, the most pessimistic analysts were assuming only about 2.7% annual revenue growth and no profitability within three years, so it is worth comparing how that cautious view of weak academic demand stacks up against the possibility that new collaborations and platforms might reshape expectations.

Explore 3 other fair value estimates on 10x Genomics - why the stock might be worth as much as 9% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your 10x Genomics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.